MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

Search

CareDx Inc

Geschlossen

BrancheGesundheitswesen

19.17 -1.59

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

18.9

Max

19.48

Schlüsselkennzahlen

By Trading Economics

Einkommen

10M

1.7M

Verkäufe

13M

100M

KGV

Branchendurchschnitt

15.641

78.892

Gewinnspanne

1.674

Angestellte

644

EBITDA

11M

6.8M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+12.94% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

279M

1.1B

Vorheriger Eröffnungskurs

20.76

Vorheriger Schlusskurs

19.17

Nachrichtenstimmung

By Acuity

50%

50%

149 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

CareDx Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Dez. 2025, 22:03 UTC

Wichtige Markttreiber

Mining Stocks Slip Near the End of Stellar Year

29. Dez. 2025, 15:57 UTC

Wichtige Markttreiber

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29. Dez. 2025, 23:43 UTC

Market Talk

Nikkei May Decline; Yen in Focus -- Market Talk

29. Dez. 2025, 23:38 UTC

Akquisitionen, Fusionen, Übernahmen

Manus: Will Continue to Operate From Singapore

29. Dez. 2025, 23:38 UTC

Akquisitionen, Fusionen, Übernahmen

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29. Dez. 2025, 23:37 UTC

Akquisitionen, Fusionen, Übernahmen

Meta Platforms: Will Integrate Manus Service Into Products

29. Dez. 2025, 23:36 UTC

Akquisitionen, Fusionen, Übernahmen

Meta Platforms: Will Continue to Operate, Sell Manus Service

29. Dez. 2025, 23:36 UTC

Akquisitionen, Fusionen, Übernahmen

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29. Dez. 2025, 23:35 UTC

Akquisitionen, Fusionen, Übernahmen

Manus to Join Meta Platforms

29. Dez. 2025, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

Origin: Raise Values Kraken at US$8.65 Billion

29. Dez. 2025, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

Origin: Octopus Targeting Kraken Separation by Mid 2026

29. Dez. 2025, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29. Dez. 2025, 21:31 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29. Dez. 2025, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Origin's Kraken Stake to Remain at 22.7%

29. Dez. 2025, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29. Dez. 2025, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29. Dez. 2025, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Origin: Additional Interest Offsets Dilution From Raise

29. Dez. 2025, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29. Dez. 2025, 21:29 UTC

Akquisitionen, Fusionen, Übernahmen

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29. Dez. 2025, 21:29 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29. Dez. 2025, 21:29 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29. Dez. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29. Dez. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29. Dez. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29. Dez. 2025, 21:28 UTC

Akquisitionen, Fusionen, Übernahmen

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29. Dez. 2025, 21:27 UTC

Akquisitionen, Fusionen, Übernahmen

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29. Dez. 2025, 20:22 UTC

Market Talk

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29. Dez. 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29. Dez. 2025, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29. Dez. 2025, 17:36 UTC

Market Talk

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Peer-Vergleich

Kursveränderung

CareDx Inc Prognose

Kursziel

By TipRanks

12.94% Vorteil

12-Monats-Prognose

Durchschnitt 22 USD  12.94%

Hoch 26 USD

Tief 18 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CareDx Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

1

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

14.77 / 18.49Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

149 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat